Phase II Of Parkinson’s Treatment Trial Starts For ChromaDex's Nicotinamide Riboside

ChromaDex completed its phase I clinical trial studying the effects of nicotinamide riboside on Parkinson’s Disease. Lead researcher Charalampos Tzoulis is “very excited about these results” and that the trial represents “a novel approach in experimental PD-therapy.”